Skip to main content

Table 2 Rabbit ACLT study—µCT data from trabecular bone

From: The selective cathepsin K inhibitor MIV-711 attenuates joint pathology in experimental animal models of osteoarthritis

Parameter

Femur

Tibia

Medial

Lateral

Medial

Lateral

Trabecular bone volume (mm3)

 Sham-vehicle

7.8 ± 0.4

5.9 ± 0.3

9.7 ± 0.7

10.7 ± 0.6*

 ACLT-vehicle

6.7 ± 0.3

4.8 ± 0.3

7.6 ± 0.7

8.1 ± 0.7

 ACLT-low dose

7.0 ± 0.7

5.3 ± 0.5

8.9 ± 0.7

9.9 ± 0.7

 ACLT-high dose

7.2 ± 0.5

5.5 ± 0.2

9.5 ± 0.5

10.3 ± 0.4*

Connective density (1/mm3)

 Sham-vehicle

8.00 ± 0.31

8.63 ± 0.50

5.79 ± 0.30*

11.35 ± 1.04*

 ACLT-vehicle

9.30 ± 0.75

12.12 ± 1.65

9.93 ± 1.29

18.17 ± 2.35

 ACLT-low dose

11.42 ± 1.61

13.51 ± 1.54

9.20 ± 1.08

16.55 ± 1.95

 ACLT-high dose

9.14 ± 0.63

11.90 ± 1.51

8.47 ± 0.69

16.25 ± 2.01

Structure model index

 Sham-vehicle

0.35 ± 0.13

0.62 ± 0.09

0.53 ± 0.09

0.52 ± 0.11

 ACLT-vehicle

0.30 ± 0.06

1.02 ± 0.09

0.79 ± 0.17

0.78 ± 0.19

 ACLT-low dose

0.48 ± 0.07

0.73 ± 0.15

0.52 ± 0.16

0.51 ± 0.12

 ACLT-high dose

0.40 ± 0.07

0.63 ± 0.11

0.41 ± 0.10

0.42 ± 0.11

Trabecular number (1/mm)

 Sham-vehicle

3.22 ± 0.28

2.32 ± 0.27

2.03 ± 0.15

2.88 ± 0.18

 ACLT-vehicle

2.79 ± 0.10

2.19 ± 0.09

1.94 ± 0.17

2.63 ± 0.14

 ACLT-low dose

3.02 ± 0.20

2.58 ± 0.16

2.05 ± 0.08

2.96 ± 0.15

 ACLT-high dose

3.71 ± 0.68

2.55 ± 0.10

2.09 ± 0.15

3.01 ± 0.16

Trabecular thickness (mm)

 Sham-vehicle

0.24 ± 0.00

0.21 ± 0.01

0.28 ± 0.01

0.24 ± 0.01*

 ACLT-vehicle

0.22 ± 0.01

0.19 ± 0.01

0.23 ± 0.01

0.19 ± 0.01

 ACLT-low dose

0.22 ± 0.03

0.18 ± 0.01

0.25 ± 0.02

0.21 ± 0.01

 ACLT-high dose

0.22 ± 0.02

0.19 ± 0.01

0.26 ± 0.00

0.22 ± 0.01

Trabecular separation (mm)

 Sham-vehicle

0.32 ± 0.03

0.48 ± 0.08

0.50 ± 0.04

0.35 ± 0.02

 ACLT-vehicle

0.36 ± 0.01

0.46 ± 0.02

0.54 ± 0.05

0.39 ± 0.02

 ACLT-low dose

0.34 ± 0.02

0.40 ± 0.03

0.49 ± 0.02

0.34 ± 0.02

 ACLT-high dose

0.30 ± 0.03

0.40 ± 0.02

0.50 ± 0.04

0.34 ± 0.02

Bone surface (mm2)

 Sham-vehicle

103.6 ± 3.6

93.9 ± 4.8

116.8 ± 4.1

143.6 ± 4.6

 ACLT-vehicle

101.7 ± 1.9

90.2 ± 2.3

119.2 ± 6.2

144.4 ± 4.4

 ACLT-low dose

105.6 ± 3.8

101.2 ± 4.3

124.9 ± 3.3

153.6 ± 4.1

 ACLT-high dose

105.2 ± 1.3

101.7 ± 2.9

124.9 ± 4.6

152.7 ± 4.1

Bone surface/volume (1/mm)

 Sham-vehicle

13.4 ± 0.2

16.0 ± 0.5

12.2 ± 0.6*

13.6 ± 0.6*

 ACLT-vehicle

15.4 ± 0.8

19.3 ± 1.6

16.1 ± 1.1

18.5 ± 1.5

 ACLT-low dose

16.0 ± 1.6

19.9 ± 1.3

14.6 ± 1.2

16.0 ± 1.2

 ACLT-high dose

15.1 ± 1.0

18.7 ± 0.8

13.2 ± 0.2

14.9 ± 0.5

Tissue mineral density (mgHA/ccm)

 Sham-vehicle

733.2 ± 9.2

709.1 ± 8.9*

743.0 ± 7.8

717.8 ± 8.4

 ACLT-vehicle

697.6 ± 8.6

670.5 ± 9.2

702.2 ± 11.4

680.2 ± 11.0

 ACLT-low dose

698.4 ± 15.7

669.6 ± 8.4

714.1 ± 13.1

700.8 ± 10.6

 ACLT-high dose

699.1 ± 10.3

673.6 ± 7.0

726.9 ± 5.5

707.0 ± 6.6

  1. * p < 0.05; vs. ACLT-vehicle group
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us